Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Prescient Therapeutics: Q&A Update with Professor H. Miles Prince Reach Markets recently interviewed Professor H....
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX) Reach Markets interviewed Co-Founder and Senior...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.